In August 2017, for the first time, a gene therapy was approved for market release in the United States. That approval was followed by two others before the end of the year. This article cites primary literature, review articles concerning particular biotechnologies, and press releases by the FDA and others in order to provide an overview of the current status
| I N TR ODU C TI ON
The past year was an important one for the field of gene therapy in the of a patient due to a systemic inflammatory response to the dosage of adenoviral vector that was administered into the patient's bloodstream. 4 In 2003, it was discovered that the theoretical risk of insertional mutagenesis (in which a viral vector can cause harm to a patient by inserting a transgene into a chromosome in a place that disrupts an existing gene in a detrimental manner) occurred at a much higher rate than expected in children being treated for severe combined immunodeficiency (SCID). 5 Over time, four out of nine of the children in the initial clinical trial developed leukemia. 6 Their leukemia was successfully treated, as was their immunodeficiency, but the rate of these detrimental side-effects, previously expected to have a vanishingly low probability of occurrence, dampened the enthusiasm for gene therapy considerably.
Indeed, the field of gene therapy has undergone the typical cycle of over-enthusiasm, disillusionment and recovery that Gartner, Inc. analysts have termed the "hype cycle." 7 My own description of hype cycle for gene therapy is portrayed in Figure 1 . However, if the field has survived its previous failures and emerged from the roller-coaster ride of the hype cycle, why does the title of this article now pose the question "how will the field survive its success?"
This is a review of the current events in the field (cited in press releases) as well as the scientific literature, to consider some challenges that may jeopardize the field's success in the foreseeable future. After enumerating and reviewing the literature regarding the hurdles that the field has mainly overcome, I consider hurdles that are not necessarily major threats to the field's success, but which are still slowing down progress. Then, I consider three more serious issues: the danger of starting a new "hype curve" rise then crash due to over-promising what results might be quickly achieved by newer gene manipulation technology, the issue of how the cost of gene therapies will be reimbursed, and finally the impending crisis in the mismatch between manufacturing capacity for viral vectors and the emerging therapies that require them.
Because many of the therapies nearing approval and all of those that have been market approved so far use viral vectors for delivery of transgenes, this review focuses on viral vectors, particularly adeno-associated virus (AAV), more than on non-viral vectors. The review closes by noting ways that bioengineers with an interest in translational medicine may find ways to contribute to solutions to at least the latter issue.
| H U R DL ES THE F I EL D HA S ( M AI N LY ) OV E RC OME
Thanks to prior decades' worth of developments in genetic engineering (the use of restriction enzymes, polymerases, ligation agents), the sequencing of the human genome, and the discovery of various ways to influence gene expression (e.g., RNA interference, 8, 9 zinc fingers 10, 11 ), it is now a straight-forward exercise to design and build a transgene for the purpose of replacing a missing gene product or reduce the production of a disease-causing gene product. A variety of ways to "package" one's transgene into a non-viral or viral vector are now also at bioengineers' disposal, ranging from nanoparticles to a variety of viral vector options (adenovirus, retroviruses, herpes simplex virus, and AAV of various serotypes). [12] [13] [14] 26 Furthermore, the delivery hurdle has a built-in "divide and conquer" aspect, in that the therapy is delivered to each eye separately.
The hurdle of the distribution of transgene products to replace or supplement enzyme deficiencies in patients is being overcome by the strategy of designing transgene products to be secretable, and delivering the transgenes to the liver with the result that the liver becomes a continuing producer of the enzyme. Aiding in this effort has been the identification of AAV serotypes with particular tropism for the liver 27 and the use of promoters specific for gene expression from hepatocytes. 28 The need in many disorders for distribution of transgene products to the central nervous system poses a bigger hurdle, however.
Proteins produced and secreted from the liver generally are excluded from distribution to the brain due to the blood-brain barrier (BBB). For (GAN). 30 However, for disorders that may benefit from or absolutely require distribution of the therapy throughout almost all of the brain, the "holy grail" to be sought is a vector capable of delivering a gene therapy across the BBB given that the vasculature is nature's distribution system for reaching the whole brain. AAV serotype 9 has an ability to cross the BBB when administered to the bloodstream, [31] [32] [33] but whether this capability is sufficient for "scale up" for human clinical efficacy remains to be seen. 34 Efforts to re-engineer the AAV9 serotype to create a novel serotype with much greater BBB-crossing capability have been successful in mice, 35 raising the possibility that this hurdle may be overcome through bioengineering. However, a recent report suggests that the means used to engineer the novel AAV serotype in mice may have resulted in a solution that is species-specific 36 or even, mouse-strain specific, 37 and not transferable to humans. Bioengineers may need to go "back to the drawing board" in this case.
Most daunting of all is the hurdle of how to deliver a transgene to large amounts of the musculature of the human body for the treatment of muscular dystrophy. Despite promising results in mouse models, therapeutic benefits in human trials have not been achieved. 38 In a proof-of-principle trial involving direct injection of AAV into quadriceps muscles in muscular dystrophy patients, no adverse effects were found, but the functional benefit was variable across individuals. 39 In a canine model of DMD, systemic (intravenous) delivery of AAV9 delivering a mini-dystrophin gene into neonatal animals resulted in generalized muscle expression of the transgene, but also caused delayed growth, muscle atrophy, and contractures. 40 More recently, it has been found that intravenous delivery of AAV9 can produce widespread and welltolerated muscle transduction of skeletal muscle, diaphragm and heart in a canine model of DMD when the delivery is made in juvenile animals and combined with ongoing immune suppression. 41 Before translation to human trials, more research will be needed to determine the long-term safety and efficacy of this approach.
| Intellectual property complexity
Another hurdle that is surmountable, but which slows down progress in the field, is the complexity of the intellectual property "territories" that can surround a given gene therapy development. Development and deployment of a new gene therapy entity may involve not only the therapeutic transgene itself, but also its mechanism of action (e.g., RNA
interference, CRISPR, etc.), the non-viral or viral vector used as the delivery agent (e.g., the particular serotype of AAV), and the method for delivery of the gene therapy to the patient (e.g., the delivery devices, surgical techniques, and treatment protocols to be used).
While use of some of these therapy components or methods may not involve any patent barriers, others may be protected by patents issued to the original inventors of a specific viral serotype or type of construct used to exploit a mechanism of action (e.g., types of RNA molecules or Another hurdle responsible for slowing the development of some gene therapies is the concern that a gene therapy is inevitably irreversible. Unlike a drug for which the administration can be discontinued or a medical device that can be turned off or explanted, a gene therapy's action may persist for many years, if not for the remainder of the patient's life. This aspect of gene therapy is an advantage with regards to efficacy, allowing for possible "once-and-done" treatments, but obviously a disadvantage with regards to safety-"there's no way to turn it off." As a consequence, regulatory bodies reasonably require preclinical safety testing for a new gene therapy to be extensive and the timing between dose-escalation cohorts and the length of trials for safety monitoring to be long. In addition, they may require the dosing of the first cohort of patients to be at a conservatively low level with the unfortunate consequence that the first patients receiving therapy are excluded from receiving the potentially greater benefit of a higher dose because, unlike drug treatments, immune response considerations might prohibit re-dosing of the gene therapy. One may speculate that if a new therapy also had an "antidote" or "safety switch" such that its administration could be reversed at will, then some of the extreme caution regarding first-in-human use of the new therapy would be mitigated. There exist some biotechnologies that could provide such a "safety switch" for gene therapies, particularly if implemented in a "platform" vector as called for by the above-mentioned NCATS call for information. 42 For example, it has long been known that inserting some particular DNA sequences (loxP sites) into a transgene can allow the intervening DNA between two of these sites to be excised by an enzyme (Cre) delivered either as a protein or as a second transgene. In a pilot study, delivery of a Cre transgene to the cerebral ventricles of a sheep to which a transgene (flanked with loxP sites) encoding for hexosaminidase enzyme had previously been delivered was successfully able to reverse the expression of the first transgene, as evidenced by the return of the newly elevated hexosaminidase enzyme levels in the animal's CSF back to its pre-treatment baseline. 43 The emergence of CRISPR gene-editing technology provides another method that might be exploited for targeting and editing-out a transgene to reverse a previously delivered gene therapy. The issue from a safety and regulatory standpoint, of course, is whether the delivery of the Cre enzyme or transgene or the CRISPR agent would be totally effective as well as safe in its own right. The undesired persistence of the Cre or CRISPR transgene could be avoided by having that transgene itself contain DNA sequences that would cause the Cre or CRISPR-Cas action to inactivate it, as well. 44 Another alternative could be the use of conditional promoters to drive transgene expression. These are promoters that are marginally active in the absence of a co-factor, such as an orally administered drug (e.g., doxycycline) so that the therapy is only "on" while the patient continues taking the oral medication. 45 However, the promoter systems available so far are "leaky" rather than absolute in their "off" state, and the drugs that are administered orally to turn on gene expression are not themselves without undesirable side-effects.
Also, the whole system might involve delivery of multiple transgenes, including a regulatory transgene that operationalizes the conditional behavior of the promoter driving expression of the therapeutic transgene, requiring the long-term safety of the system to be qualified for human use. These technical issues may be solvable; however, today, there may not be any organization with the resources or incentive to develop this platform technology for clinical use for the benefit of the whole field.
Finally, another issue many gene therapy developers must address is how to determine the appropriate size for clinical trials of a therapy for a rare or ultrarare disease, as these are the targets of many gene therapy opportunities. Unless the expected treatment effect is very large, the sample size required for a conventional, randomized controlled trial design could represent a sizeable fraction or even exceed the size of the candidate population, such that the trial is economically unfeasible due to the cost of goods, the cost of patient enrollment and monitoring, and the elimination of patients from a future therapy customer base. Of course, regulatory agencies are not unaware of this issue, and have issued guidelines indicating that "in conditions with small and very small populations, less conventional and/or less commonly seen methodological approaches may be acceptable if they help to improve the interpretability of the study results." 46 Resources that can be brought to bear on this issue include the conduct of natural history studies of the relevant patients for use as historical controls and the identification of useful outcome measures, 47 and the use of one of various alternative clinical trials designs that have been devised 48 if the design is applicable to an intervention that is irreversible.
The hurdles described above slow down the progress of the gene therapy field, but they do not threaten to "derail it" in a major way. In this author's opinion, there are three other more serious challenges
currently facing the field. The answer to "how will the field survive its success?" depends on how well these challenges are met. A second reason for caution is that the limitations of gene therapy vectors for treatments requiring distribution to the entire body, as some gene-editing treatments might require, are still being learned and may not always be appreciated. For example, a recent experiment in rhesus monkeys found that the high doses of AAV that may need to be delivered intravenously for some therapies could be prohibitively toxic. 52 In three out of three primates and three out of three piglets, the investigators found that the high doses of AAV used resulted in severe toxicity, including hepatocellular necrosis and axonopathies in both the central and peripheral nervous system of the monkeys, and neuronal degeneration in the dorsal root ganglia of the piglets. In commenting on this report, Flotte et al. 53 noted that the doses used in the animals with these serious outcomes are nevertheless being used in human trials that so far have not encountered dose-limiting toxicity, and that the toxicity encountered in the primates and piglets could have been due to some unidentified contaminants in the viral preparation. They concluded that the field must neither ignore nor overreact to these findings regarding the toxicity of high systemic doses of AAV.
| CH A LL EN GE 2: I M P LE M EN TI N G RE I M BU R SEM E NT I NN OV A TI ONS
A second major challenge to the field is the issue of how gene therapies that have achieved success in clinical development will achieve success in the marketplace. A case in point is that of Glybera for regulatory approval, 54 nevertheless, it was determined that this single-treatment therapy does provide benefit to patients, particularly by reducing the occurrence of pancreatitis, which can be lifethreatening. It was marketed in Europe in 2015 at a price equivalent to US $1 million, 55 a cost comparable to about 3 years' worth of enzyme replacement therapy (at $360,000 per year) for other enzyme deficiency disorders. 56 While this inherited disease is rare, it is not ultrarare; its prevalence is approximately 1-2 million persons worldwide.
Even so, in 2016, only one patient was treated post-market release of the therapy, and in 2017, uniQure elected not to renew its market authorization for the product.
GlaxoSmithKline (GSK) has had a similarly difficult time with their gene therapy (Strimvelis) for SCID due to adenosine deaminase deficiency. In this case, the evidence for the efficacy of the treatment and the magnitude of the benefit is overwhelming. One dose of the therapy provides what is essentially a cure for the disease-there was a survival rate of 100% of the 18 children involved in the clinical trials of the treatment. 57, 58 The therapy was priced at 594,000 Euros in 2016, with GSK also providing a "money-back guarantee." Nevertheless, as of 2017, only two patients had received the treatment with two others "in queue" to receive the therapy, and GSK was seeking a buyer for Strimvelis. 59 What is the problem? Are parents not motivated to save the lives of their children? Are the treatments too painful or too onerous to be tolerated? Have companies not sufficiently publicized the availability of these therapies? Are companies setting prices too high out of pure greed? None of the above. The problem is twofold.
First, the attractive property of many gene therapies (that they can be "once and done" lifetime treatments) coupled with the other property that the treatments are expensive not only to develop but also to provide (with a high "cost of goods") requires a high price for the therapy for its production to be economically viable. Unlike small molecule drug therapies that are expensive to develop but later less costly to manufacture, or enzyme replacement therapies that are expensive to develop and costly to produce but are not one time treatments, gene therapies do not intrinsically provide an ongoing revenue stream to the producer to recoup costs and make a profit over time.* Unlike "once and done" therapies based on capital equipment such as cardiac ablation equipment acquired by hospitals, the up-front investment cost (revenue to the manufacturer) is not amortized over time and multiple patients by the provider. Instead, the revenue needed must be derived from the patient's first and perhaps only treatment.
Second, our current systems for paying for treatments are not at all well-suited to these "front-loaded" costs. New reimbursement models are needed.
| The mismatch of once-and-done treatments and reimbursement models
Currently, in the United States, reimbursement rates tend to be based on the cost of comparable procedures performed by the health care provider in delivering treatments, plus the cost of goods and other supplies and equipment provided by the clinic or hospital. This model does not work well for a therapy for which the procedure costs are only modest (e.g., placing an intravenous line and performing an infusion) but the costs of goods is high but not-recurring. Necessarily, then, the lion's share of the reimbursement must be based on weighing the cost of goods against the benefit to the patient, moving the model from of $575,000 paid for responders at one month compares favorably with the threshold needed to achieve a rate of $100,000 per Quality Adjusted Life Year of expected benefit in these patients, one commonly used cost-effectiveness threshold.
Unfortunately, moving to the "pay for value" model for health care reimbursement still does not solve the problem of how the high up-front cost of a gene therapy can be afforded by payers, whether individuals or third-party payers. Recognizing this, companies producing gene therapies are now seeking other innovations, such as moving from "pay for value"
to a "pay for outcome" model. Novartis, provider of Kymriah, is taking this approach, offering the therapy on a "delayed payment" basis whereby payment for the treatment only is required after evidence that the therapy has worked, and the patient's cancer has gone into remission. How many months must elapse after treatment for the patient's health status to qualify as "remission" then becomes a point of debate. show (or feign) poor health in order to discontinue payments, this approach is still a mismatch to health care systems in the United States in which patients are used to being able to change insurance companies at will on an annual basis. Even more so than the contentious issue of coverage for pre-existing conditions, a payment scheme that spreads the up-front cost of a gene therapy over time may lead to controversies over whether insurers must provide coverage for persons with "pre-existing payment obligations." Nations with single-payer systems (universal health coverage provided by a government agency) may be better able to adopt this approach, and cover gene therapies despite their high cost, knowing that their system will also reap the future benefits of the cost-avoidance (e.g., for expensive palliative and end-of-life care) that an effective "once and done" treatment may provide.
It is apt that the leadership of the gene therapy company with the ticker symbol "ONCE" (Spark Therapeutics, Jeff Mazzarro, CEO) has recognized the need for innovations in reimbursement schemes for the field of gene therapy to be successful and is joining several other leaders in health care in work to meet this challenge. 62 
| CH A LL EN GE 3: M E ETI N G T HE L OOM IN G M A NU F A CTU R I NG DE M A ND
A third major challenge to the field's continued success, at least in the near term, is the challenge of developing the manufacturing capacity of the United States and other countries sufficiently to meet the coming demand for the therapeutic agents, specifically AAV production. This has not been a major challenge so far because the therapies approved 19,22 FDA approval of one or more of these therapies may be achieved within the next year or two. An idea of how much vector manufacturing capacity these therapies will require for sufficient supply of products for market success can be seen by noting the dosage expected per patient, compared to a vector genome yield that is feasible given the current state-of-the-art in AAV manufacturing, which is about 1 e 16 vector genomes per manufactured lot (see Table 1 ).
As indicated in Table 1 , whereas a single GMP lot of AAV that is qualified and released for market use might be sufficient inventory for 33,000 patients receiving an intraocular gene therapy, the same lot may only be sufficient inventory for three patients receiv- For example, uniQure has established its own manufacturing facility in Lexington, Massachusetts. Pfizer has acquired Bamboo Therapeutics, 63 a spin-off of the University of North Carolina vector core 64 to enhance AAV production capacity (which had the effect of removing some smaller organizations' access to this capacity) and they are proceeding to invest in the building of additional capacity. 65 Contract manufacturing companies are also seeing the future increased demand for viral production and are working to build more capacity. For example, Brammer Bio has recently doubled its capacity in Alachua, Florida 66 and renovated a 66,000
square foot facility in Cambridge, Massachusetts. 67 However, increasing capacity is not just a matter of adding square footage and clean rooms-there is also a need for expertise and experience, which will take time to acquire. naked siRNA molecules into the putamen in non-human primates results in their uptake and the induction of RNA interference in cells. 72, 73 Nevertheless, despite some advantages of manufacturing and using non-viral vectors compared to viral vectors for delivery of gene therapies (see Table 2 ), there are other features of viral vectors that non-viral vectors do not match, the foremost being the limited transduction efficiency of non-viral vectors compared to viral vectors. 74 As with viral vectors, the development of processes and manufacturing capacity for producing clinical grade non-viral vectors to scale will also require significant effort. If the therapeutic application involves delivery of lengthy molecules of DNA rather than chemically synthesizable oligos, then the manufacturing of non-viral vectors will benefit from bioengineering developments in the first step in viral vector manufacturing, namely the GMP production of plasmids. Successful clinical deployments of gene therapies based on non-viral vectors are at least several years away, and then, they will be unlikely to displace the role of viral vectors in the marketplace. Therefore, improvements in technology that improve the yield of viral vector manufacturing will remain an important area for bioengineers' attention.
| An example of the manufacturing processes involved: production of AAV
The production of AAV involves multiple "upstream" and "downstream"
processes. An overview of the process steps in a typical AAV manufacturing protocol is portrayed in Figure 2 . A strength for the use of non-viral vectors, depending on mechanism of action (e.g., protein replacement vs. permanent gene editing mechanism).
Ability to titrate dose to effect in patient Not possible; dose required for effectiveness is difficult to predict; requires applications with a large therapeutic window between the minimally effective dose and the maximally tolerated dose.
A strength for the use of non-viral vectors, although relationship between dose and effect must be empirically established.
Possibility for repeated dosing
Immune response to first dosing may limit effectiveness or prohibit use of an additional administrations of the same viral serotype.
Comparatively better, though an immune response to novel transgene product may still pose a limitation.
Risk of insertional mutagenesis
Not an issue for AAV; minimized in newer generations of lentivirus.
Non-existent to minimal, depending mechanism of action (e.g., transposons can insert DNA into unpredictable host chromosome locations).
For diseases with central nervous system (CNS) involvement: CNS distribution via axonal transport
Comparatively good to excellent (a feature of many AAV serotypes).
Comparatively poor to non-existent.
Neuronal specificity A feature of some AAV serotypes; can be useful for avoiding immune response in nervous system mediated by glial cells.
Carriers with neuronal specificity remain to be developed.
Crossing of the blood-brain barrier A feature of some AAV serotypes; further developments needed for clinical utility.
Requires nanoparticles with peptides or other conjugates for uptake across BBB; decades of research have not yet yielded clinically deployable solution.
Since in the downstream part of AAV production multiple process steps need to be performed in series to purify the product, clearly even if each step is 75% efficient resulting in only 25% loss of yield due to that step, it only takes a series of three steps at this efficiency to reduce the overall yield of the final product to 42% or even less, considering that some of the yield that must be devoted to in-process and final product safety, purity, and quality testing requirements.
Research is needed to improve both the upstream and downstream steps of AAV production. Bioengineering can contribute to improvements in the upstream yield of AAV through the engineering of improved bioreactor equipment. For a review and analysis of how improvements in downstream steps might be made based on the consideration of the properties of AAV, including size, mass, isoelectric point, and other physicochemical properties, see Qu et al. 78 When producing AAV for use in pre-clinical research, and particularly when producing the amount of AAV needed for studies in small animals, the loss of more than half of the amount of vector produced to the processing steps usually did not have a major impact on the availability or cost of AAV to the researcher. Now, however, a loss of more than half of the yield of a manufacturing lot of vector equates to more than a doubling of the cost of goods of the product to the clinical trialist, and ultimately to the patient receiving the marketed therapy.
Therefore, process improvements and perhaps break-through innovations are needed-worthwhile for bioengineers to devote their time, energy, expertise, and creativity to find and develop. 
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